Rapid engineering of SARS-CoV-2 therapeutic antibodies to increase breadth of neutralization including XBB.1.5 and BQ.1.1 https://www.biorxiv.org/content/10.1101/2023.01.25.525589v1?med=mas
Rapid engineering of SARS-CoV-2 therapeutic antibodies to increase breadth of neutralization including XBB.1.5 and BQ.1.1 https://www.biorxiv.org/content/10.1101/2023.01.25.525589v1?med=mas